Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 138

1.

Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.

Houts AC, Olufade T, Shenolikar R, Walker MS, Schwartzberg LS.

Cancer Treat Res Commun. 2019 Feb 6;19:100121. doi: 10.1016/j.ctarc.2019.100121. [Epub ahead of print]

PMID:
30785027
2.

Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting.

Navari RM, Schwartzberg LS.

Onco Targets Ther. 2018 Oct 4;11:6459-6478. doi: 10.2147/OTT.S158570. eCollection 2018. Review.

3.

Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy.

Schwartzberg LS, McLaughlin T, Geller RB, Gabrail NY, Marks SM.

J Comp Eff Res. 2018 Dec;7(12):1161-1170. doi: 10.2217/cer-2018-0089. Epub 2018 Oct 11.

4.

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar.

Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, Elliott C, Korrer S.

Clinicoecon Outcomes Res. 2018 Sep 3;10:493-500. doi: 10.2147/CEOR.S168298. eCollection 2018.

5.

Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.

Fisher MD, Pulgar S, Kulke MH, Mirakhur B, Miller PJ, Walker MS, Schwartzberg LS.

J Gastrointest Cancer. 2018 Aug 18. doi: 10.1007/s12029-018-0160-x. [Epub ahead of print]

PMID:
30121904
6.

Safety of Polysorbate 80 in the Oncology Setting.

Schwartzberg LS, Navari RM.

Adv Ther. 2018 Jun;35(6):754-767. doi: 10.1007/s12325-018-0707-z. Epub 2018 May 23. Review.

7.

Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans.

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Moderau N, Poyia F, Schwartzberg LS, Tabassum N, Wen J, Krell J, Stebbing J.

Oncotarget. 2018 Feb 24;9(25):17589-17596. doi: 10.18632/oncotarget.24564. eCollection 2018 Apr 3.

8.

Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.

Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, DeLeon A, Elliott C, Korrer S.

J Manag Care Spec Pharm. 2018 Oct;24(10):976-984. doi: 10.18553/jmcp.2018.17447. Epub 2018 Apr 24.

9.

An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.

Vacirca JL, Chan A, Mezei K, Adoo CS, Pápai Z, McGregor K, Okera M, Horváth Z, Landherr L, Hanslik J, Hager SJ, Ibrahim EN, Rostom M, Bhat G, Choi MR, Reddy G, Tedesco KL, Agajanian R, Láng I, Schwartzberg LS.

Cancer Med. 2018 May;7(5):1660-1669. doi: 10.1002/cam4.1388. Epub 2018 Mar 23.

10.

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.

Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang J, Xiao N, Greil R, Rinnerthaler G, Gampenrieder SP, Heimberger AB, Berry DA, Barker A, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Magee D, Miglarese MR, Famulok M, Mayer G, Spetzler D.

Nat Commun. 2018 Mar 23;9(1):1219. doi: 10.1038/s41467-018-03631-z.

11.

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Mar;16(3):310-320. doi: 10.6004/jnccn.2018.0012.

PMID:
29523670
12.

Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.

Graetz I, McKillop CN, Stepanski E, Vidal GA, Anderson JN, Schwartzberg LS.

J Cancer Surviv. 2018 Aug;12(4):431-440. doi: 10.1007/s11764-018-0682-z. Epub 2018 Feb 28.

PMID:
29492753
13.

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J.

J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26.

14.

Chemotherapy-induced nausea and vomiting: strategies for prevention and treatment.

Schwartzberg LS.

Clin Adv Hematol Oncol. 2017 Dec;15(12):906-913. No abstract available.

PMID:
29315282
15.

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L.

J Natl Compr Canc Netw. 2017 Dec;15(12):1520-1541. doi: 10.6004/jnccn.2017.0175.

PMID:
29223990
16.

Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings.

Walker MS, Wong W, Ravelo A, Miller PJE, Schwartzberg LS.

Clin Lung Cancer. 2018 Mar;19(2):139-147. doi: 10.1016/j.cllc.2017.10.003. Epub 2017 Oct 13.

PMID:
29103883
17.

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J.

Breast Cancer Res Treat. 2017 Nov;166(1):327-328. doi: 10.1007/s10549-017-4482-3. No abstract available.

PMID:
28884461
18.

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

Baselga J, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L, Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS.

Clin Breast Cancer. 2017 Dec;17(8):585-594.e4. doi: 10.1016/j.clbc.2017.05.006. Epub 2017 May 22.

19.

A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer.

Schwartzberg LS, Arena FP, Bienvenu BJ, Kaplan EH, Camacho LH, Campos LT, Waymack JP, Tagliaferri MA, Chen MM, Li D.

J Cancer. 2017 Jul 3;8(10):1872-1883. doi: 10.7150/jca.15407. eCollection 2017.

Supplemental Content

Loading ...
Support Center